Janssen (NYSE:JNJ) has submitted a supplemental New Drug Application
to the FDA, for a new indication for Spravato (esketamine) nasal spray,
for the rapid reduction of depressive symptoms in adult patients with
major depressive disorder who have active suicidal ideation with intent.
That is a population that historically has been excluded from antidepressant clinical trials, the company notes.
The sNDA is based on results from the Phase 3
ASPIRE I and II trials, which evaluated efficacy and safety of Spravato
vs. placebo in this patient population.
The FDA approved Spravato in conjunction with an
oral antidepressant for treating treatment-resistant depression in
adults on March 5.
https://seekingalpha.com/news/3503559-janssen-files-new-indication-spravato
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.